Bahram Biglari1, Axel Büchler2, Tyler Swing3, Christopher Child3, Elisabeth Biehl1, Tim Reitzel1, Tom Bruckner4, Thomas Ferbert3, Sebastian Korff3, Harald Rief5, Hans-Jürgen Gerner3, Arash Moghaddam3. 1. BG Trauma Centre Ludwigshafen, Department of Paraplegiology, Ludwigshafen, Germany. 2. Heidelberg Trauma Research Group, Trauma and Reconstructive Surgery, Department of Orthopaedics, Traumatology, and Paraplegiology, Heidelberg University Hospital, Heidelberg, Germany axel.buechler@gmx.de. 3. Heidelberg Trauma Research Group, Trauma and Reconstructive Surgery, Department of Orthopaedics, Traumatology, and Paraplegiology, Heidelberg University Hospital, Heidelberg, Germany. 4. Institute for Medical Biometry and Informatics, University Hospital of Heidelberg, Heidelberg, Germany. 5. Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
Abstract
OBJECTIVE: To determine serum concentrations of soluble CD95 ligand (sCD95L) in patients with traumatic spinal cord injury. METHODS: Patients with traumatic spinal cord injury were recruited. Blood was collected on admission to hospital and at 4 h, 9 h, 12 h, 24 h, 3 days, 7 days, and 2, 4, 8 and 12 weeks postadmission. Serum concentrations of sCD95L were determined via immunoassay. RESULT: The study included 23 patients. Mean sCD95L concentrations were significantly lower at 4 h, 9 h, 12 h and 24 h than at admission, and were significantly higher at 8 and 12 weeks, compared with admission. CONCLUSION: The serum sCD95L concentration fell significantly during the first 24 h after traumatic spinal cord injury. Concentrations then rose, becoming significantly higher than admission levels at 8 weeks. sCD95L may represent a possible therapeutic target for traumatic spinal cord injury.
OBJECTIVE: To determine serum concentrations of soluble CD95 ligand (sCD95L) in patients with traumatic spinal cord injury. METHODS:Patients with traumatic spinal cord injury were recruited. Blood was collected on admission to hospital and at 4 h, 9 h, 12 h, 24 h, 3 days, 7 days, and 2, 4, 8 and 12 weeks postadmission. Serum concentrations of sCD95L were determined via immunoassay. RESULT: The study included 23 patients. Mean sCD95L concentrations were significantly lower at 4 h, 9 h, 12 h and 24 h than at admission, and were significantly higher at 8 and 12 weeks, compared with admission. CONCLUSION: The serum sCD95L concentration fell significantly during the first 24 h after traumatic spinal cord injury. Concentrations then rose, becoming significantly higher than admission levels at 8 weeks. sCD95L may represent a possible therapeutic target for traumatic spinal cord injury.
Authors: R A Heller; T F Raven; T Swing; K Kunzmann; V Daniel; P Haubruck; M Akbar; P A Grützner; G Schmidmaier; B Biglari; A Moghaddam Journal: Spinal Cord Date: 2017-06-20 Impact factor: 2.772
Authors: C H Hulme; S J Brown; H R Fuller; J Riddell; A Osman; J Chowdhury; N Kumar; W E Johnson; K T Wright Journal: Spinal Cord Date: 2016-12-20 Impact factor: 2.772
Authors: Bahram Biglari; Raban Arved Heller; Manuel Hörner; Andre Sperl; Tobias Bock; Bruno Reible; Patrick Haubruck; Paul Alfred Grützner; Arash Moghaddam Journal: J Spinal Cord Med Date: 2019-06-18 Impact factor: 1.985
Authors: Arash Moghaddam; Christopher Child; Thomas Bruckner; Hans Jürgen Gerner; Volker Daniel; Bahram Biglari Journal: Int J Mol Sci Date: 2015-04-09 Impact factor: 5.923